Aryl Hydrocarbon Receptor (AhR)

(Note: This is not a nuclear receptor, although it shares many characteristics of the family. AHR is a member of the basis-helix-loop-helix, PAS domain (bHLH-PAS) family.) This gene encodes a ligand-activated transcription factor involved in the regulation of biological responses to planar aromatic hydrocarbons. This receptor has been shown to regulate xenobiotic-metabolizing enzymes such as cytochrome P450. Its ligands included a variety of aromatic hydrocarbons.

[provided by RefSeq, Jul 2008]

NRR Pathway


Aryl Hydrocarbon Receptor Structure

(From Structure)


There are 218 articles specifically referring to this gene in PubMed. Functionally, the gene has been tested for association to diseases (Adenocarcinoma; Adenoma; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Transformation, Neoplastic; Chloracne; Endometriosis; Esophageal Neoplasms; Genetic Predisposition to Disease and 13 others), proposed to participate in a pathway (Ahr Signal Transduction Pathway) and processes (positive regulation of RNA polymerase II transcriptional preinitiation complex assembly, positive regulation of transcription, DNA-dependent, prostate gland development). Proteins are expected to have molecular function (sequence-specific DNA binding) and to localize in cytoplasm. Putative protein interactors have been described (AHR, AIP, AR, ARNT, ARNTL, CCNT1_, CUL4B, DAP3, EP300, ESR1 and 21 others).

(From HuGENavigator)

  • Lung Neoplasms
  • Breast Neoplasms
  • Endometriosis
  • Infertility, Male
  • Colorectal Neoplasms
  • Lymphoma, Non-Hodgkin
  • Neoplasms
  • Urinary Bladder Neoplasms
  • DNA Damage
  • Nervous System Diseases
  • Occupational Diseases
  • Carcinoma, Squamous Cell
  • Alzheimer Disease
  • Adenocarcinoma
  • Adenoma
  • Abnormalities
  • Abnormalities
  • Autonomic Nervous System Diseases
  • Brain Neoplasms
  • Carcinoma, Small Cell
  • Communicable Diseases
  • Coronary Artery Disease
  • Cryptorchidism
  • Dementia
  • Diabetes Complications
  • Diabetes Mellitus
  • Disease Susceptibility
  • Cardiovascular Diseases
  • Chronic Disease
  • Cleft Lip
  • Cleft Palate
  • Glioma
  • Hypersensitivity
  • Hypertension
  • Hypospadias
  • Macular Degeneration
  • Metabolic Syndrome X
  • Micronuclei, Chromosome-Defective
  • Multiple Myeloma
  • Kidney Failure, Chronic
  • Laryngeal Neoplasms
  • Esophageal Neoplasms
  • Oligospermia
  • Osteoporosis
  • Prostatic Neoplasms
  • Pulmonary Disease, Chronic Obstructive
  • Sleep Initiation and Maintenance Disorders
  • Stomach Neoplasms
  • Neuropsychological Tests
  • Neurotoxicity Syndromes
  • Neoplasms, Second Primary
  • Neoplasms, Squamous Cell
  • Vitiligo

Assay Kits and Services are available from INDIGO Biosciences.

Kits are offered in different assay formats to accommodate researchers' needs: 3x 32, 1x 96, and 1x 384 assay formats for screening small numbers of test compounds, as well as custom bulk reagents for HTS applications. Assay systems are all inclusive, providing reporter cells, optimized growth media, media for diluting test compounds, a positive-control agonist, luciferase detection reagent, a white assay plate, a detailed protocol, and a protocol quick guide. All kits are shipped on dry ice.

AhR Reporter Cells are prepared using INDIGO’s proprietary CryoMite™ process. This cryo-preservation method yields high cell viability post-thaw, and provides the convenience of immediately dispensing healthy, division-competent reporter cells into assay plates. There is no need for intermediate spin-and-wash steps, viability determinations, or cell titer adjustments.

The principle application of this assay product is in the screening of test samples to quantify functional activities, either agonist or antagonist, that they may exert against the aryl hydrocarbon receptor. This kit product is an all-inclusive assay system that includes, in addition to AhR Reporter Cells, two optimized media for use during cell culture and (optionally) in diluting the test samples, a reference agonist, Luciferase Detection Reagent, a cell culture-ready assay plate, and a detailed protocol.


(From Aceview)

The gene contains13 distinct gt-ag introns. Transcription produces 6 different mRNAs, 5 alternatively spliced variants and 1 unspliced form. There are 3 probablealternative promotors, 2 non overlapping alternative last exons and 5 validated alternative polyadenylation sites (see the diagram). The mRNAs appear to differ by truncation of the 5' end, truncation of the 3' end, overlapping exons with different boundaries, splicing versus retention of one intron. 270 bp of this gene are antisense to spliced gene loyky, raising the possibility of regulated alternate expression. Note that mRNA .bAug10 was found in vivo, although it is a predicted target of nonsense mediated mRNA decay (NMD).


AHR, AIP, AR, ARNT, ARNTL, CCNT1_, CUL4B, DAP3, EP300, ESR1 and 21 others

(From KEGG)

None noted


(From BioGPS)